about
Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation.Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines.Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential.Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes.Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation.Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.Thiomaltol-Based Organometallic Complexes with 1-Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior.Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers.Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography.Microfluidic 68Ga-labeling: a proof of principle study.Development and evaluation of a rapid analysis for HEPES determination in Ga-radiotracersMolar activity - The keystone in C-radiochemistry: An explorative study using the gas phase methodBrain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapyNovel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agentsOptimization of the Automated Synthesis of [11C]mHED—Administered and Apparent Molar ActivitiesAn Overview of PET Radiochemistry, Part 1: The Covalent Labels 18F, 11C, and 13NImpact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate 11C-Metoclopramide Assessed with PET Imaging in HumansThe effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomographyL-[S-methyl-11C]methionine - An example of radiosynthetic optimizationAssessment of Myocardial Viability in Ischemic Heart Disease by PET/MRI: Comparison of Left Ventricular Perfusion, Hibernation, and Scar BurdenModeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imagingTechnical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramideSerotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MRAssessment of sympathetic reinnervation after cardiac transplantation using hybrid cardiac PET/MRI: A pilot studyCharacterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using 18F-FDG-PET/CT and 18F-NaF-PET/CT
P50
Q38795441-E18A4F30-C40E-49DC-9BBD-A7245269B2AEQ38864172-330FFE30-FB43-4758-AD17-B1DDF720CDC8Q38941379-C03CFFF0-4015-42B2-BA5E-05660217603CQ39136834-EDC4C4C6-6FA4-47B6-9DED-FE906DE2C5E3Q39196999-F4337D98-F5F6-404C-9977-C85E2F641FE6Q39235908-DDFD460B-8DC1-413B-AF3E-A320F9CEA1C5Q42173414-541172C7-DE7D-4AB0-8C81-DF0C1F36F37CQ46417081-83AA80CE-D6E0-4110-B073-FDB22324E85BQ46475362-DB36EA3B-02C3-489C-8768-53999EC0C8E7Q47206511-F03A268C-BD82-4970-A2C8-532D6B7D3D50Q50089992-B078794B-90B3-4433-A776-F996B3B8A3F3Q52583481-E20FD00B-6E95-40B8-8330-E2AC62B85262Q57796783-B9799901-7D76-43B5-AA60-158AC28D2035Q58122829-FFDA13C3-5ACF-4DE3-85D2-A0F1C4D907D5Q58705329-96CCDF71-3FF3-40AD-81D1-5F0E4A4CE2BFQ60240420-E228CDA0-6C40-4D1D-8BFB-283EF131B252Q62862485-EA5B642F-B566-4FB7-89E8-4B4714CF457EQ90451007-B4FD132F-A7DD-4798-8FF7-C8E0FB85117DQ90989080-F9FDA525-126C-40A2-A031-FDDA9D653E3DQ91009126-7DBF6CAD-020E-4F31-8316-C610D9A542CAQ91342572-94C789A7-49DC-4EE7-AFC2-EADC478DBC57Q91749888-AB744AEC-9BB5-4219-9720-74A7079557B4Q91926628-842F2E1C-866F-46AE-95B2-1FD5D90FC5E7Q91971802-014E754D-D119-418D-A732-F799EC8639BAQ92104038-4D21F2C0-6743-4079-951D-CA3EBE96AEFAQ92237637-0FA137AE-D9C1-4535-BFF4-6AE682F96206Q92501431-FC6E6A81-FBC2-4676-9FCA-5879F4099628Q92885098-57D497DB-2FF3-47C3-80A2-9F7FF666F28A
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-4544-2438
@en
name
Verena Pichler
@ast
Verena Pichler
@en
Verena Pichler
@es
Verena Pichler
@nl
type
label
Verena Pichler
@ast
Verena Pichler
@en
Verena Pichler
@es
Verena Pichler
@nl
prefLabel
Verena Pichler
@ast
Verena Pichler
@en
Verena Pichler
@es
Verena Pichler
@nl
P106
P1153
57200194854
P31
P496
0000-0003-4544-2438